
Relmada Therapeutics Inc (NASDAQ:RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results.
Relmada Therapeutics reported quarterly losses of $1.80 per share which beat the analyst consensus estimate of a loss of $1.83. Goldman Sachs Thursday maintained Relmada Therapeutics with a Buy and lowered the price target from $69 to $53.